Concord Biotech is currently trading at Rs. 1291.95, up by 3.30 points or 0.26% from its previous closing of Rs. 1288.65 on the BSE.
The scrip opened at Rs. 1294.85 and has touched a high and low of Rs. 1320.50 and Rs. 1283.75 respectively. So far 6259 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1979.20 on 24-Jul-2025 and a 52 week low of Rs. 987.05 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1377.95 and Rs. 1283.50 respectively. The current market cap of the company is Rs. 13499.15 crore.
The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 17.02% and 38.90% respectively.
Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully.
The successful completion of PPB and NDA inspection marks a significant step in the company’s global growth journey. This achievement reinforces its commitment to the highest standards of quality and regulatory excellence while strengthening its global manufacturing and regulatory footprint.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.15 |
| Dr. Reddys Labs. | 1350.00 |
| Cipla | 1440.30 |
| Zydus Lifesciences | 1101.50 |
| Lupin | 2342.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: